Paper Details

  1. Home
  2. Paper Details

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.

Author: AndersonK, ColemanM, CooperM R, KochwaS, KyleR A, McIntyreO R, PragerD, PropertK J, RaflaS, ZimmerB

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 615 patients with multiple myeloma found that four different IV alkylating agent regimens led to similar response rates. The sequential regimen was associated with poorer survival. Melphalan/prednisone is recommended as initial therapy.
Paper Details　
Original Abstract of the Article :
Four intravenous (IV) alkylating agent regimens were tested in 615 previously untreated patients with multiple myeloma. Patients were randomized to receive melphalan, cyclophosphamide, and carmustine in combination (MCBP), sequentially (Seq-MCBP), or in combination with doxorubicin (MCBPA). The four...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1986.4.9.1331

データ提供：米国国立医学図書館（NLM）

Alkylating Agents for Multiple Myeloma: A Comparative Study

The battle against cancer is a complex and ever-evolving landscape, with researchers constantly searching for more effective and targeted treatments. This study examines the use of various alkylating agents, a class of chemotherapy drugs, for treating multiple myeloma, a type of blood cancer. The researchers compared the efficacy and safety of four different alkylating agent regimens in a large group of patients with multiple myeloma.

Alkylating Agent Regimens: A Comparative Analysis

The study found that while all four alkylating agent regimens demonstrated similar response rates, the survival rates differed significantly. Patients receiving a sequential regimen (Seq-MCBP) had a significantly poorer survival compared to the other groups. Interestingly, the survival of patients with a high tumor cell load and azotemia (high nitrogen levels in the blood) was better in the groups treated with single-agent melphalan or a combination of melphalan, cyclophosphamide, and carmustine (MCBP).

Navigating Multiple Myeloma Treatment: A Personalized Approach

This research highlights the importance of individualizing treatment decisions for multiple myeloma, taking into account factors like tumor cell load and overall health status. It's like navigating a vast desert, where the best route depends on the specific challenges and resources available. The findings suggest that a personalized approach to treatment, tailored to the individual patient's needs, could lead to more favorable outcomes.

Dr.Camel's Conclusion

This study is a valuable contribution to the field of multiple myeloma research. It provides a comprehensive comparison of different alkylating agent regimens, offering insights into the nuances of treatment selection and highlighting the importance of a personalized approach to maximize the benefits and minimize the risks associated with chemotherapy.

Date :
  1. Date Completed 1986-10-06
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

3528403

DOI: Digital Object Identifier

10.1200/JCO.1986.4.9.1331

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.